As previously reported, Guggenheim initiated coverage of WW with a Buy rating and $14 price target, calling it “a high-risk, high-reward opportunity to play the GLP-1 theme at a time when the stock appears to price in most of the downside risk.” The firm, which sees CEO Sima Sistani as close to stabilizing a reinvigorated legacy WW business and thinks the recently acquired Sequence asset gives WW a scalable Clinical business, views WW as “positioned as well as any business to capture demand for GLP-1 companion lifestyle modification programs” and expresses confidence that management will execute that strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WW:
- WeightWatchers Launches New Behavior Change Program Designed to Support the Unique Needs of Individuals on GLP-1 Medications
- WW lauches WeightWatchers GLP-1 Program
- WW falls after Oprah reveals use of weight-loss drug to People
- Weight Watchers call volume above normal and directionally bullish
- WW International, Inc. Announces Participation in Upcoming Investor Conferences